



NYSE:VNRX

Our mission is to save lives and improve outcomes for millions of people and animals worldwide by advancing low-cost, epigenetic early detection and treatment monitoring tests.

Commercial launches worldwide in animal health (2022-2024); human products to follow

Combined TAM >\$10 billion

Derisked R&D and Commercial Strategy: Reported First \$1 million Revenue 2024

Commercial Progress

- Nu.Q® Vet Cancer test now available in 20+ countries
- Sold ~120,000 tests and test components in 2024
- Received \$23 million in upfront and milestone payments to-date
 - Additional \$5 million milestone payment (feline) anticipated
- **Multiple international partnerships launched**
- **TAM >\$750 million**

Revenue Expansion

- Simple, low cost, recurring revenue generating tests performed on standard lab equipment
- **Clinical Partnering: multiple near-term licensing opportunities progressing**
- **Direct and indirect sales of CE-marked products in Europe, as hospitals evaluate for routine clinical use**

Large Unmet Needs

- **Lung Cancer Screening** – screening, prognostics and MRD represent a \$4B opportunity
- **Sepsis** – testing and monitoring ICU patients alone is a ~\$1B+ opportunity
- **Other addressable markets** of include Acute Kidney Injury (AKI), Acute Respiratory Distress Syndrome (ARDS) and use in the Emergency Department **>\$10B** opportunity

Strong IP*

- 71 patents granted
- 130 pending internationally
- Patent coverage up to 2044

Licensing Portfolio: Platform stable, reproducible

Application	Proof of Concept	Viability	Validation	Licensed
Animal				
Canine Cancer Screening	→	→	→	✓ Launched
Canine Cancer Monitoring	→	→	→	✓
Feline Cancer	→	→	→	✓
Automated tests	→	→	→	Fujifilm Vet Systems
Human				
Sepsis	→	→	→	Data room available
Cancer	→	→	→	Data room available
Lung Cancer Screening	→	→	→	Data room available
Minimal Residual Disease & Disease Management	→	→	→	Data room available
Multi-Cancer Early Detection	→	→	→	Data room available
Capture-PCR™/Capture-Seq™	→	→	→	Data room available

NYSE Ticker: VNRX (ISIN US9286611077) <https://volition.com>

This document may include forward-looking statements. Forward-looking statements express current expectations, projections and forecasts of future events or long-term goals and, by their nature, are subject to assumptions, risks and uncertainties. Any of those assumptions, current expectations and projections could prove to be inaccurate and, as a result, the forward-looking statements also could be materially incorrect. Actual results could differ materially from those indicated. VolitionRx undertakes no obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise. Nucleosomics™, Capture-PCR™/Capture-Seq™, and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. * as of March 31st 2025